Zacks: Brokerages Expect Teleflex Incorporated (NYSE:TFX) to Post $3.37 Earnings Per Share

Wall Street analysts expect that Teleflex Incorporated (NYSE:TFXGet Rating) will post $3.37 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Eleven analysts have issued estimates for Teleflex’s earnings, with the lowest EPS estimate coming in at $3.28 and the highest estimate coming in at $3.52. Teleflex posted earnings of $3.35 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 0.6%. The firm is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Teleflex will report full-year earnings of $14.00 per share for the current financial year, with EPS estimates ranging from $13.91 to $14.14. For the next fiscal year, analysts forecast that the business will report earnings of $15.51 per share, with EPS estimates ranging from $15.00 to $15.98. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Teleflex.

Teleflex (NYSE:TFXGet Rating) last released its earnings results on Thursday, April 28th. The medical technology company reported $2.88 EPS for the quarter, beating the Zacks’ consensus estimate of $2.72 by $0.16. Teleflex had a return on equity of 17.44% and a net margin of 17.31%. The business had revenue of $641.70 million for the quarter, compared to analysts’ expectations of $631.89 million. During the same quarter in the prior year, the firm earned $2.87 earnings per share. The firm’s revenue was up 1.2% on a year-over-year basis.

A number of analysts have recently weighed in on TFX shares. Zacks Investment Research lowered shares of Teleflex from a “hold” rating to a “sell” rating and set a $373.00 target price for the company. in a report on Friday, April 1st. StockNews.com started coverage on shares of Teleflex in a report on Thursday, March 31st. They set a “buy” rating for the company. Morgan Stanley dropped their target price on shares of Teleflex from $383.00 to $378.00 and set an “equal weight” rating for the company in a report on Friday, February 25th. Piper Sandler increased their target price on shares of Teleflex from $320.00 to $335.00 in a report on Thursday, February 24th. Finally, Raymond James dropped their target price on shares of Teleflex from $391.00 to $370.00 and set an “outperform” rating for the company in a report on Wednesday, February 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Teleflex has a consensus rating of “Buy” and an average price target of $394.58.

NYSE TFX opened at $282.53 on Tuesday. The company has a quick ratio of 1.40, a current ratio of 2.10 and a debt-to-equity ratio of 0.46. The company has a 50-day simple moving average of $336.37 and a two-hundred day simple moving average of $331.55. The firm has a market cap of $13.25 billion, a price-to-earnings ratio of 27.46, a PEG ratio of 1.57 and a beta of 1.06. Teleflex has a 12-month low of $277.02 and a 12-month high of $428.36.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 15th. Shareholders of record on Monday, March 7th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date was Friday, March 4th. Teleflex’s dividend payout ratio is 13.22%.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. HighTower Advisors LLC grew its position in Teleflex by 0.8% in the third quarter. HighTower Advisors LLC now owns 4,652 shares of the medical technology company’s stock valued at $1,759,000 after acquiring an additional 36 shares in the last quarter. Veritable L.P. raised its stake in shares of Teleflex by 4.9% during the third quarter. Veritable L.P. now owns 793 shares of the medical technology company’s stock valued at $299,000 after purchasing an additional 37 shares in the last quarter. Avalon Investment & Advisory raised its stake in shares of Teleflex by 1.6% during the third quarter. Avalon Investment & Advisory now owns 2,661 shares of the medical technology company’s stock valued at $1,002,000 after purchasing an additional 41 shares in the last quarter. Mutual of America Capital Management LLC raised its position in Teleflex by 0.7% in the third quarter. Mutual of America Capital Management LLC now owns 6,149 shares of the medical technology company’s stock worth $2,315,000 after acquiring an additional 42 shares in the last quarter. Finally, Ieq Capital LLC raised its position in Teleflex by 0.7% in the first quarter. Ieq Capital LLC now owns 6,088 shares of the medical technology company’s stock worth $2,160,000 after acquiring an additional 42 shares in the last quarter. 92.21% of the stock is owned by institutional investors and hedge funds.

Teleflex Company Profile (Get Rating)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Further Reading

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.